

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-32. (Cancelled)

33. (Currently Amended) A compound, which is
4-ethoxy-6-fluoroquinoline-2-carboxylic acid;
4-((E)-4-[(2-carboxy-6-fluoro-4-quinolinyloxy)-2-butenyl]oxy)-6-fluoroquinoline-2-carboxylic acid;
6-fluoro-4-(3-methylbut-2-enyloxy)quinoline-2-carboxylic acid;
4-[2-(3,4-dimethoxyphenyl)-2-oxo-ethoxy]-6-fluoroquinoline-2-carboxylic acid;
methyl 4-(3-chloropropoxy)-6-fluoroquinoline-2-carboxylate; or
methyl 4-(3-chloro-2-methylpropoxy)-6-fluoroquinoline-2-carboxylate; or
a pharmaceutically acceptable salt thereof, or
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

34. (Currently Amended) A compound according to claim 33, which is
4-ethoxy-6-fluoroquinoline-2-carboxylic acid;
4-((E)-4-[(2-carboxy-6-fluoro-4-quinolinyloxy)-2-butenyl]oxy)-6-fluoroquinoline-2-carboxylic acid;
6-fluoro-4-(3-methylbut-2-enyloxy)quinoline-2-carboxylic acid;
4-[2-(3,4-dimethoxyphenyl)-2-oxo-ethoxy]-6-fluoroquinoline-2-carboxylic acid;
methyl 4-(3-chloropropoxy)-6-fluoroquinoline-2-carboxylate; or
methyl 4-(3-chloro-2-methylpropoxy)-6-fluoroquinoline-2-carboxylate; or
a pharmaceutically acceptable salt thereof.

35. (Currently Amended) A pharmaceutical composition, comprising a compound of claim 33 and a pharmaceutically acceptable carrier.

36. (Currently Amended) A pharmaceutical composition, comprising a compound of claim 34 and a pharmaceutically acceptable carrier.

37. (Currently Amended) A method for treating ~~or preventing~~ a hyperglycaemia-related pathology, which is diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 35.

38. (Currently Amended) A method according to claim 37, which is for treating diabetes, ~~type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or~~ hyperglycaemia.

39. (Currently Amended) A method for treating ~~or preventing~~ a hyperglycaemia-related pathology, which is diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 36.

40. (Currently Amended) A method according to claim 39, which is for treating diabetes, type II diabetes, ~~dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or~~ hyperglycaemia.

41. (New) A compound according to claim 33, which is 4-ethoxy-6-fluoroquinoline-2-carboxylic acid; a pharmaceutically acceptable salt thereof, or a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

42. (New) A compound according to claim 33, which is 4-({(E)-4-[(2-carboxy-6-fluoro-4-quinolinyl)oxy]-2-butenyl}oxy)-6-fluoroquinoline-2-carboxylic acid; a pharmaceutically acceptable salt thereof, or a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

43. (New) A compound according to claim 33, which is
6-fluoro-4-(3-methylbut-2-enyloxy)quinoline-2-carboxylic acid;
a pharmaceutically acceptable salt thereof, or
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.
44. (New) A compound according to claim 33, which is
4-[2-(3,4-dimethoxyphenyl)-2-oxo-ethoxy]-6-fluoroquinoline-2-carboxylic acid;
a pharmaceutically acceptable salt thereof, or
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.
45. (New) A compound according to claim 33, which is
methyl 4-(3-chloropropoxy)-6-fluoroquinoline-2-carboxylate;
a pharmaceutically acceptable salt thereof, or
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.
46. (New) A compound according to claim 33, which is
methyl 4-(3-chloro-2-methylpropoxy)-6-fluoroquinoline-2-carboxylate,
a pharmaceutically acceptable salt thereof, or
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.
47. (New) A method according to claim 37, which is for treating type II
diabetes.
48. (New) A method according to claim 37, which is for treating
hyperglycaemia.
49. (New) A method according to claim 37, which is for treating obesity.
50. (New) A method according to claim 37, which is for treating arterial
hypertension.
51. (New) A method according to claim 37, which is for treating
atherosclerosis.

52. (New) A method according to claim 37, which is for treating dyslipidaemia, microangiopathy, macroangiopathy, retinopathy or neuropathy.